688098 Stock Overview
Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 5/6 |
Dividends | 1/6 |
Shanghai Shen Lian Biomedical Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥5.47 |
52 Week High | CN¥8.34 |
52 Week Low | CN¥4.18 |
Beta | 0.68 |
1 Month Change | -2.50% |
3 Month Change | -26.48% |
1 Year Change | -32.47% |
3 Year Change | -57.13% |
5 Year Change | n/a |
Change since IPO | -85.14% |
Recent News & Updates
Recent updates
Shareholder Returns
688098 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -5.7% | -4.3% | -4.9% |
1Y | -32.5% | -11.8% | -16.6% |
Return vs Industry: 688098 underperformed the CN Pharmaceuticals industry which returned -11.4% over the past year.
Return vs Market: 688098 underperformed the CN Market which returned -14.8% over the past year.
Price Volatility
688098 volatility | |
---|---|
688098 Average Weekly Movement | 8.0% |
Pharmaceuticals Industry Average Movement | 7.0% |
Market Average Movement | 8.2% |
10% most volatile stocks in CN Market | 11.5% |
10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 688098's share price has been volatile over the past 3 months.
Volatility Over Time: 688098's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 365 | Xu Gao | https://www.slbio.com.cn |
Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. It develops synthetic peptide vaccines to treat foot-and-mouth diseases. The company was founded in 2001 and is headquartered in Shanghai, China.
Shanghai Shen Lian Biomedical Corporation Fundamentals Summary
688098 fundamental statistics | |
---|---|
Market cap | CN¥2.25b |
Earnings (TTM) | CN¥31.52m |
Revenue (TTM) | CN¥301.49m |
71.3x
P/E Ratio7.5x
P/S RatioIs 688098 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688098 income statement (TTM) | |
---|---|
Revenue | CN¥301.49m |
Cost of Revenue | CN¥0 |
Gross Profit | CN¥301.49m |
Other Expenses | CN¥269.97m |
Earnings | CN¥31.52m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 27, 2024
Earnings per share (EPS) | 0.077 |
Gross Margin | 100.00% |
Net Profit Margin | 10.45% |
Debt/Equity Ratio | 0.08% |
How did 688098 perform over the long term?
See historical performance and comparison